Question 1

What are the potential benefits of participating in this trial compared to standard treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from Tilsotolimod?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or complications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any additional tests or procedures required if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma clinical trial (NCT04126876). Contact the study team or your healthcare provider for specific answers.

What this study is about